Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer

Published:2023-01 Issue: Volume:78 Page:100291
ISSN:1807-5932
Container-title:Clinics
language:en
Short-container-title:Clinics

Author:

Liu Qi^ORCID,Hou Lingli^ORCID,Zhao Ying^ORCID,Yang Hongwei^ORCID,Mo Zhengying^ORCID,Yu Fei^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030;Lei;Cancer Biol Med,2021

2. Overcoming endocrine resistance in breast cancer;Hanker;Cancer Cell,2020

3. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

4. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo;Xiong;Biomed Pharmacother,2019

5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial;Tripathy;Lancet Oncol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP